MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13216-13228

  Dou, Changwei ^a   Wang, Yufeng ^a   Li, Chao ^a   Liu, Zhikui ^a   Jia, Yuli ^a   Li, Qing ^a   Yang, Wei ^a   Yao, Yingmin ^a   Liu, Qingguang ^a   Tu, Kangsheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; FOXA1; Hepatocellular carcinoma; MiR 212; Proliferation

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MICRORNA; MICRORNA 212; UNCLASSIFIED DRUG; FOXA1 PROTEIN, HUMAN; MIRN212 MICRORNA, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84931027844     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3916     Document Type: Article

References (35)

1. Yates LA, Norbury CJ and Gilbert RJ. The long and short of microRNA. Cell. 2013;153:516-519.
2. Lujambio A and Lowe SW. The microcosmos of cancer. Nature. 2012;482:347-355.
3. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V and Russo A. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Tar. 2012;16:S103-S109.
4. Chang RM, Yang H, Fang F, Xu JF and Yang LY. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60:1251-1263.
5. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y and Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer research. 2009;69:1135-1142.
6. Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH and Qin LX. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 2014;59:1874-1885.
7. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, Baldwin AS, Jr., Fisher PB and Sarkar D. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. The Journal of biological chemistry. 2012;287:13952-13958.
8. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY and Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897-907.
9. Giordano S and Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013; 57:840-847.
10. Cho WCS. MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell B. 2010;42:1273-1281.
11. Ucar A, Vafaizadeh V, Jarry H, Fiedler J, Klemmt PA, Thum T, Groner B and Chowdhury K. miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nature genetics. 2010;42:1101-1108.
12. Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C, Iaboni M, Nuovo G, Croce CM and Condorelli G. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer research. 2010;70:3638-3646.
13. Jiping Z, Ming F, Lixiang W, Xiuming L, Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C and Jihui J. MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. Journal of cellular biochemistry. 2013;114:2666-2672.
14. Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, Yu H, Zuo Y, Pan Z, Liu RY and Huang W. Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology. 2013;145:426-436 e421-426.
15. Walter BA, Valera VA, Pinto PA and Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. Journal of Cancer. 2013;4:350-357.
16. Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H, Wang W, Huang X, Yuan Z and Ai K. miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. Journal of experimental & clinical cancer research: CR. 2014;33:54.
17. Wang SC, Lin XL, Li J, Zhang TT, Wang HY, Shi JW, Yang S, Zhao WT, Xie RY, Wei F, Qin YJ, Chen L, Yang J, Yao KT and Xiao D. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA. PloS one. 2014;9:e101330.
18. Bandiera S, Pfeffer S, Baumert TF and Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol. 2015;62:448-457.
19. Wang B, Hsu SH, Wang X, Kutay H, Bid HK, Yu J, Ganju RK, Jacob ST, Yuneva M and Ghoshal K. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. Hepatology. 2014;59:555-566.
20. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M and Brown M. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15:3680-3689.
21. Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner JM, Zynger DL, Eeckhoute J, Yu J, Luo J, Brown M, Clinton SK, Nephew KP, Huang TH, Li W and Wang Q. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer research. 2011;71:6738-6748.
22. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H and Badve S. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast cancer research and treatment. 2012;131:881-890.
23. Li Z, Tuteja G, Schug J and Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012;148:72-83.
24. Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang X, Weng W, Pan Q, Yu Y, Sun F and Wang J. Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. Cellular signalling. 2014;26:2961-2968.
25. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
26. Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, Lewis BC, Ji H and Mao J. TRIB2 acts downstream of Wnt/ TCF in liver cancer cells to regulate YAP and C/EBPalpha function. Molecular cell. 2013;51:211-225.
27. Taube JH, Allton K, Duncan SA, Shen L and Barton MC. Foxa1 functions as a pioneer transcription factor at transposable elements to activate Afp during differentiation of embryonic stem cells. The Journal of biological chemistry. 2010;285:16135-16144.
28. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255.
29. Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S and Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. Journal of hepatology. 2014;61:1088-1096.
30. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576-4585.
31. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ. Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Mol Ther. 2011;19:1116-1122.
32. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA and Jacks T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. P Natl Acad Sci USA. 2008;105:3903-3908.
33. Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y and Liu Q. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Molecular cancer. 2014;13:110.
34. Tu K, Zheng X, Zhou Z, Li C, Zhang J, Gao J, Yao Y and Liu Q. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PloS one. 2013;8:e68574.
35. Zheng X, Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler AL, Elsawa SF, Vrabel AM, Shire AM, Comba A, Thorgeirsson SS, Kim Y, Liu Q, Fernandez-Zapico ME, et al. The transcription factor GLI1 mediates TGFbeta1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism. PloS one. 2012;7:e49581.